Augmentin chewable tablets are prescription-only antibacterial products containing amoxicillin and clavulanate potassium in a chewable oral dosage form. The July 2026 U.S. FDA prescribing information identifies four branded chewable strength pairs: 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg. The first number identifies amoxicillin, a penicillin-class antibacterial, while the second identifies clavulanic acid supplied as clavulanate potassium. Because each product contains two active components, Augmentin chewables are different from plain amoxicillin chewable tablets.
The four presentations form two component-ratio families. The 125/31.25 mg and 250/62.5 mg tablets have a 4:1 amoxicillin-to-clavulanic-acid ratio, while the 200/28.5 mg and 400/57 mg products have approximately 7:1 ratios. FDA labeling also distinguishes the branded strengths by color, flavor and imprint. These details matter because the conventional Augmentin 250 mg/125 mg tablet is not interchangeable with the 250 mg/62.5 mg chewable tablet, despite their identical amoxicillin quantities. In addition, the branded 200/28.5 mg and 400/57 mg chewables contain aspartame, a source of phenylalanine relevant to patients with phenylketonuria.
For U.S. families evaluating an existing prescription, the central task is to verify the exact chewable strength pair, dosage form, approved product and applicable dispensing instructions. Branded and generic presentations can have different markings, inactive ingredients and packaging, while FDA approval records do not guarantee local stock or clinical suitability. This page focuses on chewable product identification and formulation-specific considerations; the conventional Augmentin tablets guide and oral suspension guide cover those separate dosage forms.
Augmentin chewable tablets are a distinct oral dosage form within the amoxicillin/clavulanate family. Each tablet contains amoxicillin, supplied as amoxicillin trihydrate, and clavulanic acid, supplied as clavulanate potassium. Amoxicillin acts against susceptible bacteria by interfering with bacterial cell-wall synthesis, while clavulanate inhibits certain beta-lactamase enzymes that can otherwise inactivate amoxicillin. The combination does not overcome every resistance mechanism and is not automatically preferable to plain amoxicillin.
Unlike conventional film-coated Augmentin tablets, chewables have their own strength pairs, physical characteristics and inactive-ingredient profiles. Some branded strengths contain particular flavorings, color additives or sweeteners that can matter when verifying the prescribed product. A chewable tablet should therefore not be treated as a conventional tablet presented in a different shape.
These formulations are particularly relevant to pediatric prescribing, but the presence of a chewable option does not establish suitability for every child. A healthcare professional must determine the appropriate medicine, strength and administration instructions according to the infection and patient circumstances. The product names and quantities described here are identification information, not dosing recommendations.
The Augmentin brand overview explains the wider branded family, while the generic amoxicillin/clavulanate guide covers the two-ingredient medicine and its regulatory identity. This page addresses the four chewable presentations specifically.
The July 2026 FDA prescribing information identifies four branded Augmentin chewable strengths: 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg. Each pair describes the amounts of amoxicillin and clavulanic acid in one chewable tablet. These quantities should not be confused with concentrations per 5 mL or with a complete prescribed regimen.
The 125/31.25 mg and 250/62.5 mg products share a 4:1 ingredient ratio. The 200/28.5 mg and 400/57 mg products have approximately 7:1 ratios. Within each family, the higher labeled strength contains twice the amounts of both active components. This relationship describes composition; it does not authorize independent changes to tablet quantities or establish which strength is clinically preferable.
FDA labeling describes the branded 125/31.25 mg and 250/62.5 mg chewables as mottled yellow, round and lemon-lime flavored, with BMP 189 and BMP 190 markings, respectively. The branded 200/28.5 mg and 400/57 mg products are mottled pink, round, biconvex and cherry-banana flavored, with AUGMENTIN 200 and AUGMENTIN 400 markings.
These appearance and imprint descriptions apply to the specified branded products. Approved generics may differ in shape, color, flavor, imprint or inactive ingredients while meeting applicable regulatory requirements. A physical tablet should always be reconciled with its dispensing label and actual product information rather than identified solely from an online photograph.
| Chewable strength | Amoxicillin | Clavulanic acid | Ratio | FDA-described branded appearance |
|---|---|---|---|---|
| 125 mg/31.25 mg | 125 mg | 31.25 mg | 4:1 | Mottled yellow, round, lemon-lime flavored; BMP 189 imprint. |
| 200 mg/28.5 mg | 200 mg | 28.5 mg | Approximately 7:1 | Mottled pink, round, biconvex, cherry-banana flavored; AUGMENTIN 200 imprint. |
| 250 mg/62.5 mg | 250 mg | 62.5 mg | 4:1 | Mottled yellow, round, lemon-lime flavored; BMP 190 imprint. |
| 400 mg/57 mg | 400 mg | 57 mg | Approximately 7:1 | Mottled pink, round, biconvex, cherry-banana flavored; AUGMENTIN 400 imprint. |
The inactive ingredients of Augmentin chewables differ between branded formulation families. The 125 mg/31.25 mg and 250 mg/62.5 mg products include ingredients such as mannitol, sodium saccharin, flavorings and D&C Yellow No. 10. The 200 mg/28.5 mg and 400 mg/57 mg presentations list aspartame and FD&C Red No. 40 among their inactive ingredients. These distinctions should be checked against the actual product label when an excipient is clinically relevant.
Aspartame is a source of phenylalanine. The FDA identifies 2.1 mg phenylalanine per branded 200 mg/28.5 mg chewable tablet and 4.2 mg per branded 400 mg/57 mg chewable tablet. Phenylalanine can be harmful to patients with phenylketonuria, or PKU, making the exact formulation important during prescribing and pharmacy review.
The branded 125 mg/31.25 mg and 250 mg/62.5 mg presentations do not list aspartame among their inactive ingredients. However, this does not establish that every generic product of those strengths has an identical excipient profile. FDA-approved generics may use different flavoring or sweetening systems within applicable regulatory requirements.
A patient with PKU or another relevant ingredient concern should have the specific medicine reviewed by a clinician and pharmacist. The presence or absence of aspartame is a formulation-identification consideration, not a reason to select a different chewable strength or change treatment independently.
| Branded chewable strength | Notable formulation details | Labeled phenylalanine information |
|---|---|---|
| 125 mg/31.25 mg | Lemon-lime flavored; sodium saccharin and D&C Yellow No. 10 among listed inactive ingredients. | Aspartame is not listed for this branded presentation. |
| 200 mg/28.5 mg | Cherry-banana flavored; contains aspartame and FD&C Red No. 40. | 2.1 mg phenylalanine per tablet. |
| 250 mg/62.5 mg | Lemon-lime flavored; sodium saccharin and D&C Yellow No. 10 among listed inactive ingredients. | Aspartame is not listed for this branded presentation. |
| 400 mg/57 mg | Cherry-banana flavored; contains aspartame and FD&C Red No. 40. | 4.2 mg phenylalanine per tablet. |
Augmentin chewable tablets are relevant to pediatric treatment when a healthcare professional determines that the combination and dosage form are appropriate. The FDA labeling includes chewable formulations for specified pediatric populations and bacterial indications, including patients weighing less than 40 kg. It also provides distinct guidance for very young infants, for whom an oral suspension may be the appropriate labeled formulation.
A child's age or preference for chewable medicine does not determine the correct strength. Prescribing decisions depend on the infection, weight, clinical history, patient characteristics and the applicable product labeling. The four available chewable strengths should not be interpreted as an age-based selection chart.
Chewables have practical administration characteristics that differ from film-coated tablets and reconstituted liquids. However, difficulty swallowing a conventional tablet does not automatically justify replacing it with a chewable strength. The pharmacist or prescriber must evaluate any formulation change and ensure the instructions match the actual product.
If a prescribed chewable product is unavailable or a child cannot use it appropriately, families should seek professional guidance rather than estimating an equivalent number of tablets or switching to a liquid concentration independently. The Augmentin prescription evaluation guide covers the broader clinical assessment required before treatment.
Conventional Augmentin tablets and chewables contain the same two active ingredients but have different dosage forms and, in some cases, different component ratios. The clearest example is the conventional 250 mg/125 mg tablet compared with the 250 mg/62.5 mg chewable. Both contain 250 mg of amoxicillin, but the conventional tablet contains twice as much clavulanic acid.
The FDA specifically identifies these two products as not substitutable. The conventional 250/125 mg tablet has a 2:1 component ratio, while the 250/62.5 mg chewable has a 4:1 ratio. Matching the amoxicillin quantity is therefore insufficient to establish equivalence. The FDA formulation-switching table also lists no corresponding chewable or suspension strength for the conventional 250/125 mg tablet.
Another FDA restriction concerns replacing one conventional 500 mg/125 mg tablet with two conventional 250 mg/125 mg tablets. Although the amoxicillin total would be 500 mg in either case, the two lower-strength tablets would contain 250 mg of clavulanic acid rather than 125 mg. These restrictions illustrate why both active-component quantities matter.
The Augmentin 250/125 mg tablet guide explains that conventional presentation in detail. The Augmentin tablets overview compares all three standard film-coated strengths without treating them as interchangeable with chewables.
| Product | Amoxicillin | Clavulanic acid | FDA labeling distinction |
|---|---|---|---|
| 250 mg/62.5 mg chewable tablet | 250 mg | 62.5 mg | Not interchangeable with the conventional 250/125 mg tablet. |
| 250 mg/125 mg conventional tablet | 250 mg | 125 mg | No equivalent chewable or suspension strength identified in FDA Table 6. |
Each of the four standard Augmentin chewable strengths has a numerically corresponding standard oral suspension concentration. The chewable strength is expressed per tablet, while the suspension concentration is expressed per 5 mL after reconstitution. The FDA identifies corresponding chewable and suspension products as containing the same nominal amounts of amoxicillin and clavulanic acid in those respective units.
The July 2026 FDA prescribing information recognizes certain chewable-to-suspension substitutions on a milligram-for-milligram basis. However, a matching strength pair does not eliminate the need for appropriate professional review. The FDA also specifies patient-population restrictions, including conditions for chewable tablets used as substitutes in pediatric patients weighing less than 40 kg.
Table 6 identifies the 125/31.25 mg and 250/62.5 mg chewable or suspension strength families in relation to the conventional 500/125 mg tablet. It identifies the 200/28.5 mg and 400/57 mg families in relation to the conventional 875/125 mg tablet. No corresponding strength is listed for the conventional 250/125 mg tablet. These are regulatory formulation relationships, not instructions for converting a prescription independently.
Chewables and oral suspensions also differ in handling and inactive ingredients. Suspension requires reconstitution, concentration-based measurement and specific storage instructions. Chewable tablets have their own package and excipient characteristics. A corresponding active-component strength does not mean that every practical or clinical feature is identical.
The Augmentin oral suspension guide covers liquid concentrations, bottle preparation and refrigerated storage. Readers examining the conventional tablets referenced in FDA Table 6 can consult the 500/125 mg tablet guide and 875/125 mg tablet guide.
| Chewable tablet strength | Corresponding standard oral suspension | FDA formulation relationship |
|---|---|---|
| 125 mg/31.25 mg | 125 mg/31.25 mg per 5 mL | Matching nominal active-component quantities per tablet and per 5 mL. |
| 200 mg/28.5 mg | 200 mg/28.5 mg per 5 mL | Matching nominal active-component quantities per tablet and per 5 mL. |
| 250 mg/62.5 mg | 250 mg/62.5 mg per 5 mL | Matching nominal active-component quantities per tablet and per 5 mL. |
| 400 mg/57 mg | 400 mg/57 mg per 5 mL | Matching nominal active-component quantities per tablet and per 5 mL. |
Augmentin chewables contain amoxicillin and clavulanate potassium. Plain amoxicillin chewable tablets contain amoxicillin without clavulanate and therefore represent a different prescription medicine. The added beta-lactamase inhibitor may change activity against certain susceptible bacteria, but it does not make Augmentin universally preferable. The Augmentin vs amoxicillin comparison explains this distinction.
Augmentin XR is a separate extended-release tablet containing 1,000 mg of amoxicillin and 62.5 mg of clavulanic acid per tablet. Its release characteristics and labeled product requirements differ from standard chewables. Similar ingredient names or approximate total milligram amounts do not justify substitution between XR and immediate-release formulations.
Augmentin ES-600 is a distinct pediatric oral suspension containing 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL after reconstitution. It has its own labeled indications and substitution restrictions. The fact that standard chewables and ES-600 contain the same two active ingredients does not make them equivalent.
The Augmentin XR guide and Augmentin ES-600 guide explain those specialized products. This chewable page maintains the boundary between conventional chewable formulations and separately labeled XR or ES-600 products.
Augmentin is the proprietary brand name, while generic chewable products may be labeled amoxicillin and clavulanate potassium. An independently approved generic is generally authorized through an Abbreviated New Drug Application, or ANDA, and must meet applicable FDA requirements for its particular reference product, dosage form and strength.
Approved generics can differ from branded chewables in imprint, color, flavoring, inactive ingredients and packaging within applicable regulatory standards. These differences do not automatically indicate inferior quality or an incorrect medicine. However, matching the ingredient names alone is not enough to establish therapeutic equivalence across different strengths or dosage forms.
The FDA Orange Book provides approved-product and applicable therapeutic-equivalence information. An authorized generic is a different regulatory category from an independently approved ANDA generic because it is marketed under the original brand drug's approved NDA without the brand name. The actual approval relationship must be verified for the specific product.
Manufacturer, labeler and repackager names may also differ. An NDC supports identification of a listed product or package but does not independently prove FDA approval, authenticity or current pharmacy stock. The FDA-approved Augmentin products guide examines approval records, while the generic manufacturers directory addresses applicant and labeler identities.
Augmentin chewable tablets are prescription-only medicines. Legitimate U.S. dispensing requires a valid prescription and compliance with applicable pharmacy requirements. The first verification step is to confirm the complete drug name, both active ingredients and the exact chewable strength pair rather than relying on an abbreviated listing such as Augmentin 200 mg.
The dosage form should match the prescription. A conventional film-coated tablet, chewable tablet, oral suspension, XR tablet or ES-600 suspension cannot be selected as an unrestricted alternative simply because the products contain amoxicillin and clavulanate. Any proposed change must be assessed under the applicable FDA labeling, prescription restrictions and state dispensing requirements.
The pharmacy should be able to identify the actual branded or generic product, its manufacturer or labeler, relevant NDC and dispensed quantity. If inactive ingredients matter, the current product labeling should also be reviewed, particularly for aspartame and phenylalanine. Historical FDA or DailyMed listings do not establish which products are currently stocked.
Families should clarify unexpected changes in tablet appearance, strength or prescribed instructions before administration. If the exact chewable formulation is unavailable, a pharmacist or prescriber must determine whether an appropriate alternative exists. Questions about lawful purchasing and pharmacy services are addressed in the Augmentin buying guide and the Augmentin online pharmacy guide.
| Verification item | What to confirm | Why it matters |
|---|---|---|
| Prescription | Valid prescription identifying the intended medicine | Augmentin chewables are not over-the-counter products. |
| Active ingredients | Amoxicillin and clavulanate potassium | Distinguishes the combination from plain amoxicillin. |
| Strength pair | 125/31.25, 200/28.5, 250/62.5 or 400/57 mg, as prescribed | Both component quantities identify the correct product. |
| Dosage form | Chewable tablet | Avoids confusion with conventional tablets and oral suspensions. |
| Brand or generic | Actual approved and dispensed product | A brand-name catalog heading does not guarantee a branded package. |
| Inactive ingredients | Current label, including relevant sweeteners or additives | Important for formulation-specific concerns such as PKU. |
| Manufacturer and NDC | Actual labeler and package identifiers | Supports identification without proving current stock. |
| Substitution | Applicable FDA labeling, prescription restrictions and professional requirements | Prevents inappropriate changes between dosage forms or strengths. |
Chewable Augmentin tablets have different handling requirements from reconstituted oral suspension. The July 2026 FDA labeling specifies tablet storage at or below 25°C (77°F), with applicable original-container instructions. Chewables do not require reconstitution, and the refrigeration and 10-day discard rules for prepared oral suspension should not automatically be applied to them. Product-specific storage and expiration instructions remain important.
The medicine contains amoxicillin, a penicillin-class antibacterial, and is subject to the FDA's warnings and contraindications for serious hypersensitivity reactions to the product or other beta-lactam antibacterial drugs. Previous Augmentin-associated cholestatic jaundice or hepatic dysfunction is also a contraindication. Potential adverse reactions include diarrhea, nausea, vomiting and skin reactions; serious risks include anaphylaxis, severe skin reactions, liver injury and Clostridioides difficile-associated diarrhea.
The specific chewable formulation can introduce additional concerns. The branded 200/28.5 mg and 400/57 mg products contain aspartame and labeled amounts of phenylalanine relevant to PKU. The FDA labeling also discusses precautions and interactions involving medications such as probenecid, oral anticoagulants and allopurinol. The prescribing clinician and pharmacist should assess these factors when relevant.
Augmentin does not treat viral illnesses such as influenza or the common cold. Patients should not share prescription antibiotics, use leftovers for a new illness or change chewable quantities independently. Severe breathing difficulty or swelling of the face or throat requires emergency medical attention. Readers seeking more detail about reported penicillin hypersensitivity can consult the penicillin allergy guide.
An FDA-labeled chewable strength is not a guarantee of current retail availability. Branded and generic products may differ in distribution, packaging and pharmacy inventory. Approval records and published product labeling identify regulatory products but do not establish that a particular pharmacy can dispense every listed strength.
When evaluating a pharmacy listing, the relevant question is whether the quoted product matches the prescribed chewable strength and whether it is branded or generic. A price for conventional Augmentin tablets or oral suspension should not be treated as a price for chewables. Actual out-of-pocket costs depend on the product, quantity, pharmacy, insurance benefits and applicable discounts.
If the prescribed chewable product is unavailable, the pharmacist should determine whether a legally and clinically appropriate alternative can be supplied or whether the prescriber must authorize a change. The existence of a corresponding liquid concentration does not authorize independent substitution.
The Augmentin price guide covers broader branded-product costs, while generic amoxicillin/clavulanate pricing addresses generic cost considerations. Prescription delivery questions belong in the Augmentin delivery guide. This page does not promise prices, stock, insurance coverage or delivery.
Augmentin chewable tablets are prescription antibacterial products containing amoxicillin and clavulanate potassium. They are a distinct oral dosage form with specific FDA-labeled strength pairs and formulation characteristics, not plain amoxicillin chewable tablets.
The July 2026 FDA prescribing information identifies four branded strengths: 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per chewable tablet. The first number identifies amoxicillin and the second identifies clavulanic acid.
The 125/31.25 mg and 250/62.5 mg chewables have a 4:1 amoxicillin-to-clavulanic-acid ratio. The 200/28.5 mg and 400/57 mg strengths have approximately 7:1 ratios. These numbers describe ingredient proportions and do not establish comparative clinical superiority or an appropriate dose.
No. Chewable and conventional film-coated tablets are different dosage forms and can contain different amoxicillin-to-clavulanate ratios. The FDA specifically identifies the 250/62.5 mg chewable tablet as not interchangeable with the conventional 250/125 mg tablet.
No. Although both contain 250 mg of amoxicillin, the chewable contains 62.5 mg of clavulanic acid while the conventional tablet contains 125 mg. The FDA explicitly identifies these products as not substitutable.
FDA labeling recognizes corresponding standard chewable and oral suspension strengths on a milligram-for-milligram basis under specified conditions. One chewable contains the same nominal active-component quantities as 5 mL of the corresponding suspension. However, changes require professional review and must comply with applicable patient-population restrictions.
Augmentin chewables are conventional oral combination formulations, not Augmentin XR extended-release tablets. XR has different strength proportions and release characteristics and should not be treated as interchangeable with chewable products.
The July 2026 FDA label describes the 125/31.25 mg and 250/62.5 mg strengths as mottled yellow, lemon-lime-flavored tablets marked BMP 189 and BMP 190. The 200/28.5 mg and 400/57 mg strengths are mottled pink, cherry-banana-flavored tablets marked AUGMENTIN 200 and AUGMENTIN 400. Generic appearances may differ.
The branded 200/28.5 mg and 400/57 mg chewables contain aspartame. The branded 125/31.25 mg and 250/62.5 mg formulations do not list aspartame among their inactive ingredients. Generic products require separate label verification.
The FDA labeling identifies 2.1 mg phenylalanine per branded 200/28.5 mg chewable tablet and 4.2 mg per branded 400/57 mg chewable tablet. Patients with phenylketonuria should have the exact prescribed product reviewed by their clinician and pharmacist.
The FDA labels chewable tablets for specified pediatric populations and bacterial indications. Suitability depends on factors including age, weight, the infection and the ability to use the dosage form. A healthcare professional must determine the appropriate medicine and regimen.
Chewable formulations should not be assumed suitable for infants. The FDA provides distinct guidance for pediatric patients younger than three months, including specified oral suspension formulations. Product selection requires professional clinical assessment.
No. Augmentin ES-600 is a separate pediatric oral suspension containing 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL. Its indications and substitution restrictions differ from standard Augmentin chewables.
An appropriately FDA-approved generic may be therapeutically equivalent to its corresponding branded reference product when applicable regulatory requirements are met. The exact strength, dosage form, approval relationship and substitution rules must be verified. Generic flavor, appearance and inactive ingredients may differ.
The July 2026 FDA label specifies storage of the tablet products at or below 25°C (77°F). Families should follow the actual dispensed product's storage and expiration instructions. Refrigeration and the 10-day discard rule for reconstituted oral suspension do not automatically apply to chewables.
No. Augmentin chewable tablets are prescription-only antibacterial medicines in the United States. Lawful dispensing requires a valid prescription and compliance with applicable pharmacy requirements. Online product listings do not establish prescription-free access.
Check the dispensing label for both active ingredients, the complete strength pair and the chewable dosage form. Ask the pharmacist to confirm the actual brand or generic product, manufacturer or labeler, tablet markings and NDC where applicable. Relevant inactive ingredients should also be verified.
Augmentin contains amoxicillin, a penicillin-class antibacterial. FDA labeling contraindicates its use in patients with a history of serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs. A reported allergy requires professional evaluation before prescribing.